174 related articles for article (PubMed ID: 32007440)
41. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer.
Guadagni F; Riondino S; Formica V; Del Monte G; Morelli AM; Lucchetti J; Spila A; D'Alessandro R; Della-Morte D; Ferroni P; Roselli M
World J Gastroenterol; 2017 Jul; 23(28):5187-5195. PubMed ID: 28811713
[TBL] [Abstract][Full Text] [Related]
42. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.
Mandala M; Clerici M; Corradino I; Vitalini C; Colombini S; Torri V; De Pascale A; Marsoni S
Ann Oncol; 2012 Jun; 23(6):1416-21. PubMed ID: 22052988
[TBL] [Abstract][Full Text] [Related]
43. The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma.
Kirkizlar O; Alp Kirkizlar T; Umit EG; Asker I; Baysal M; Bas V; Gulsaran SK; Demirci U; Demir AM
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):542-547. PubMed ID: 32245743
[TBL] [Abstract][Full Text] [Related]
44. Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin
Goel R; Fleischman AN; Tan T; Sterbis E; Huang R; Higuera C; Parvizi J; Rothman RH
Bone Joint J; 2018 Jan; 100-B(1 Supple A):68-75. PubMed ID: 29292343
[TBL] [Abstract][Full Text] [Related]
45. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
Marciniak CM; Kaplan J; Welty L; Chen D
PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
[TBL] [Abstract][Full Text] [Related]
46. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.
Hiraide M; Shiga T; Minowa Y; Nakano Y; Yoshioka H; Suzuki K; Yasuda C; Takahashi H; Hama T
J Cardiol; 2020 Jan; 75(1):110-114. PubMed ID: 31416782
[TBL] [Abstract][Full Text] [Related]
47. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Bamias A; Tzannis K; Harshman LC; Crabb SJ; Wong YN; Kumar Pal S; De Giorgi U; Ladoire S; Agarwal N; Yu EY; Niegisch G; Necchi A; Sternberg CN; Srinivas S; Alva A; Vaishampayan U; Cerbone L; Liontos M; Rosenberg J; Powles T; Bellmunt J; Galsky MD;
Ann Oncol; 2018 Feb; 29(2):361-369. PubMed ID: 29077785
[TBL] [Abstract][Full Text] [Related]
48. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
49. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience.
Kang MJ; Ryoo BY; Ryu MH; Koo DH; Chang HM; Lee JL; Kim TW; Kang YK
Eur J Cancer; 2012 Mar; 48(4):492-500. PubMed ID: 22169121
[TBL] [Abstract][Full Text] [Related]
50. Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors.
Kartolo A; Yeung C; Moffat GT; Hanna L; Hopman W; Baetz T
Immunotherapy; 2022 Jan; 14(1):23-30. PubMed ID: 34758641
[No Abstract] [Full Text] [Related]
51. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
Hurwitz HI; Saltz LB; Van Cutsem E; Cassidy J; Wiedemann J; Sirzén F; Lyman GH; Rohr UP
J Clin Oncol; 2011 May; 29(13):1757-64. PubMed ID: 21422411
[TBL] [Abstract][Full Text] [Related]
52. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
Gulati S; Hsu CY; Shah S; Shah PK; Zon R; Alsamarai S; Awosika J; El-Bakouny Z; Bashir B; Beeghly A; Berg S; de-la-Rosa-Martinez D; Doroshow DB; Egan PC; Fein J; Flora DB; Friese CR; Fromowitz A; Griffiths EA; Hwang C; Jani C; Joshi M; Khan H; Klein EJ; Heater NK; Koshkin VS; Kwon DH; Labaki C; Latif T; McKay RR; Nagaraj G; Nakasone ES; Nonato T; Polimera HV; Puc M; Razavi P; Ruiz-Garcia E; Saliby RM; Shastri A; Singh SRK; Tagalakis V; Vilar-Compte D; Weissmann LB; Wilkins CR; Wise-Draper TM; Wotman MT; Yoon JJ; Mishra S; Grivas P; Shyr Y; Warner JL; Connors JM; Shah DP; Rosovsky RP;
JAMA Oncol; 2023 Oct; 9(10):1390-1400. PubMed ID: 37589970
[TBL] [Abstract][Full Text] [Related]
53. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.
Fuentes HE; Oramas DM; Paz LH; Wang Y; Andrade XA; Tafur AJ
J Gastrointest Cancer; 2018 Dec; 49(4):415-421. PubMed ID: 28634671
[TBL] [Abstract][Full Text] [Related]
54. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.
Overvad TF; Ording AG; Nielsen PB; Skjøth F; Albertsen IE; Noble S; Vistisen AK; Gade IL; Severinsen MT; Piazza G; Larsen TB
Blood Adv; 2022 May; 6(10):2967-2976. PubMed ID: 35045569
[TBL] [Abstract][Full Text] [Related]
55. The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE.
Yhim HY; Jang MJ; Kwak JY; Yim CY; Choi WI; Lee YC; Lee JO; Lee KW; Bang SM; Kim SH; Kim YK; Chang HJ; Oh D;
Thromb Res; 2013 Apr; 131(4):e133-40. PubMed ID: 23399441
[TBL] [Abstract][Full Text] [Related]
56. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort.
Gade IL; Braekkan SK; Naess IA; Hansen JB; Cannegieter SC; Overvad K; Jensvoll H; Hammerstrøm J; Blix K; Tjønneland A; Kristensen SR; Severinsen MT
J Thromb Haemost; 2017 Aug; 15(8):1567-1575. PubMed ID: 28585779
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness and safety of extended-duration prophylaxis for venous thromboembolism in major urologic oncology surgery.
Kukreja JE; Levey HR; Scosyrev E; Kiernan M; Berrondo C; McNamee C; Wu G; Joseph JV; Ghazi A; Rashid H; Dozier A; Messing EM
Urol Oncol; 2015 Sep; 33(9):387.e7-16. PubMed ID: 25637953
[TBL] [Abstract][Full Text] [Related]
58. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
59. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
[TBL] [Abstract][Full Text] [Related]
60. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
